Icon plc Aktie
155,35 €
Deine Einschätzung
Icon plc Aktie
Was spricht für und gegen Icon plc in den nächsten Jahren?
Pro
Kontra
Rendite von Icon plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Icon plc | 1,74 % | 1,70 % | 8,75 % | -23,06 % | -24,40 % | -13,21 % | - |
| Alkermes plc | -0,82 % | 1,68 % | 0,00 % | -13,57 % | -13,57 % | 0,37 % | 40,70 % |
| Ironwood Pharmaceuticals | -0,74 % | -9,46 % | -4,96 % | -37,38 % | -36,19 % | -76,72 % | -72,65 % |
| Novocure Ltd | -2,28 % | 7,34 % | 8,63 % | -61,54 % | -61,33 % | -84,92 % | -91,96 % |
Kommentare
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the





